tbuckley/cabot-search huggingface dataset:
Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example
Authors: Haitham A. Badr, Dina M.M. AlSadek, Motawa E. El-Houseini, Christopher T. Saeui, Mohit P. Mathew, Kevin J. Yarema, Hafiz Ahmed
Journal: Biomaterials (2016)
Functional Analysis of FOXO3A Involved in Erythroid Differentiation
Authors: Hai Wang, Yadong Yang, Hongzhu QU, Xiuyan Ruan, Zhaojun Zhang, Qian Xiong, Heyuan Qi, George Stamatoyannopoulos, John A. Stamatoyannopoulos, Xiangdong Fang
Journal: Blood (2012)
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study
Authors: Philippe Rousselot, Marie Magdeleine Coudé, Françoise Huguet, Marina Lafage, Thibaut Leguay, Celia Salanoubat, Francis Witz, Magda Alexis, Maud Janvier, Mathilde Hunault, Philippe Agape, Christian Berthou, Eric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumedaly Reman, Bruno Lioure, Jean-Michel Cayuela, Sandrine Hayette, Nicola Gokbuget, Dieter Hoelzer, Andre Delannoy, Carlo Gambacorti-Passerini, Renato Bassan, Josep-Maria Ribera, Sebastian Giebel, Herve Dombret, Oliver G. Ottmann
Journal: Blood (2012)
Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL)
Authors: Kaylin Marie McMahon, Cristina Scielzo, Lydia Scarfo, Pamela Ranghetti, Shuo Yang, Leo I. Gordon, Frank Giles, Colby Shad Thaxton, Paolo Ghia
Journal: Blood (2015)
High CR-Rate after Intensive Chemotherapy but Disappointing Results after Palliative Treatment in Patients with Acute Myeloid Leukemia Above the Age of 60 Years: An Analysis of the AML97#38 Study of the East German Hematology and Oncology Study Group (OSHO).
Authors: Cornelia Becker, R. Krahl, H.K. Al Ali, W. Poenisch, M. Cross, S. Heyn, A. Gerhardt, A. Schulze, U. Mahlknecht, D. Haehling, M. Schulze, M. Freund, E. Kettner, G. Doelken, H.H. Wolf, E. Zschuppe, N. Peter, A. Franke, U. Wedding, L. Uharek, U. Kreibich, A. Florschuetz, B. Opitz, N. Zojer, W. Helbig, Dietger Niederwieser
Journal: Blood (2007)
Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Sandra Eder, Eric Beohou, Myriam Labopin, Jaime Sanz, Jürgen Finke, William Arcese, Reuven Or, Francesca Bonifazi, Agostino Cortelezzi, Ignazio Majolino, Andrea Bacigalupo, Alexandros Spyridonidis, Emilio Paolo Alessandrino, Sebastian Giebel, Mohamad Mohty, Arnon Nagler
Journal: Blood (2015)
Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification
Authors: Doreen te Raa, Perry Moerland, Alexander Leeksma, Ingrid Derks, Martin Loden, Veronika Navrkalova, Martin Trbusek, Dieuwertje Luijks, Thorsten Zenz, Anna Skowronska, Tatjana Stankovic, Mels Hoogendoorn, Marinus H. J. van Oers, Eric Eldering, Arnon P. Kater
Journal: Blood (2015)
A Phase IIIb Study of Rituximab Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy - MAXIMA-Protocol.
Authors: Manfred Hensel, Mathias Witzens-Harig, Peter Dreger, Anthony D. Ho, Daniel Thurley, Stephan Oertel
Journal: Blood (2006)
The development and validation of the Bronchiectasis Health Questionnaire
Authors: Arietta Spinou, Richard J. Siegert, Wei-jie Guan, Amit S. Patel, Harry R. Gosker, Kai K. Lee, Caroline Elston, Michael R. Loebinger, Robert Wilson, Rachel Garrod, Surinder S. Birring
Journal: European Respiratory Journal (2017)

Health-related quality of life or health status is significantly impaired in bronchiectasis. There is a paucity of brief, simple-to-use, disease-specific health status measures. The aim of this study was to develop and validate the Bronchiectasis Health Questionnaire (BHQ), a new health status measure that is brief and generates a single overall score. Patients with bronchiectasis were recruited from two outpatient clinics, during a clinically stable stage. The development of the questionnaire followed three phases: item generation and item reduction using Rasch analysis, validation, and repeatability testing. The BHQ was translated into 11 languages using standardised methodology. 206 patients with bronchiectasis completed a preliminary 65-item questionnaire. 55 items were removed due to redundancy or poor fit to the Rasch model. The final version of the BHQ consisted of 10 items. Internal consistency was good (Cronbach's α=0.85). Convergent validity of the BHQ with the St George's Respiratory Questionnaire was high (r= −0.82; p&lt;0.001) and moderate with lung function (forced expiratory volume in 1 s % predicted r= −0.27; p=0.001). There was a significant association between BHQ scores and number of exacerbations of bronchiectasis in the last 12 months (p&lt;0.001), hospital admissions (p=0.001) and computed tomography scan bronchiectasis pulmonary lobe counts (p&lt;0.001). BHQ scores were significantly worse in patients with sputum bacterial colonisation versus no colonisation (p=0.048). The BHQ was highly repeatable after 2 weeks (intraclass correlation coefficient 0.89). The BHQ is a brief, valid and repeatable, self-completed health status questionnaire for bronchiectasis that generates a single total score. It can be used in the clinic to assess bronchiectasis from the patient's perspective.
Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)
Authors: Sumithira Vasu, Samantha M. Jaglowski, Susan Geyer, Anissa Bingman, Patrick Elder, Jianhua Yu, Leslie A Andritsos, William Blum, Rebecca B Klisovic, Sam Penza, Yvonne A Efebera, Craig C. Hofmeister, Don M. Benson, Natarajan Muthusamy, Steven M. Devine, Gerard Lozanski
Journal: Blood (2012)
Limited Phase I Trial of Sequential High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia.
Authors: Bayard L. Powell, James Lovato, Claire Kimbrough, Susan Lyerly, Sonya Galloway-Daniels, Cathy Motley, Robin Harrelson, Yi Kong Keung, Mohan C. Thakuri, Istvan Molnar, Denise Levitan, David Duane Hurd
Journal: Blood (2006)
Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study
Authors: Nathan H Fowler, Sattva S. Neelapu, Fredrick B Hagemeister, Peter McLaughlin, Larry W. Kwak, Jorge E Romaguera, Michelle A. Fanale, Luis E Fayad, Robert Z. Orlowski, Michael Wang, Francesco Turturro, Yasuhiro Oki, Linda Catherine Lacerte, Felipe Samaniego
Journal: Blood (2012)
SP0083 Balancing Work and Life: “When Is A Man A Man ?”
Authors: F. Demtröder
Journal: Annals of the Rheumatic Diseases (2016)

Working is a very important part of our life. There are lots of problems and barriers for people with chronic rheumatic diseases in starting a professional career. Furthermore it is a challenge to stay in the working process for many years. Great and never ending efforts are needed to get over multiple obstacles. But are there special aspects for men? And (why) is working so important especially for men? What is the meaning of working? What are the goals of working for our life and living? And what does it mean with respect to any “treat to target”? How can we be successful and what is success? Do we have to accept limits? And what strategies are available to manage a successful working life being a man with a chronic rheumatic disease? Even if we do not find any answers let us shed some light on these important questions from a patient9s view. <h3>Conclusion</h3> To be successful for men with rheumatic diseases in balancing work and life the following strategies might be helpful: Ability to work must be kept in mind when thinking of “treat to target” in people with chronic rheumatic diseases. Obstacles can be overcome and problems can be solved by multiple different solutions. Goals should be looked at from different points of view – particularly from the patient9s perspective. The aims should be tailored in an individual way to achieve personally defined success and happiness. Life is what you make it – especially in RHEUMATISM! Right Help Empowers Us – More Action Towards Independent Self-Management. <h3>Disclosure of Interest</h3> None declared
A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma
Authors: Lauren Held, Jon P. Gockerman, Louis F. Diehl, Carlos Manuel de Castro, Joseph O. Moore, David A. Rizzieri, Gwynn D. Long, Mitchell E. Horwitz, Nelson J. Chao, Cristina Gasparetto
Journal: Blood (2011)
Disruption of Mitochondrial Phosphatase Ptpmt1 Induces Bioenergetic Stress and Differentiation Block in Hematopoietic Stem Cells
Authors: Wen-Mei Yu, Xia Liu, Jinhua Shen, Olga Jovanovic, Elena E. Pohl, Stanton L. Gerson, Toren Finkel, Hal E. Broxmeyer, Cheng-Kui Qu
Journal: Blood (2012)
SAT0507 Comparison of Oral Splinting and Kinesiotaping in Temporomandibular Joint Pain
Authors: K. Baklaci
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Kinesiotaping is widely used in pain due to various musculoskeletal conditions. Especially sports injuries are the main area for kinesiotaping. <h3>Objectives</h3> In our study we aimed to use in different topic, temporomandibular joint (TMJ) pain and to show the efficacy on joint function and quality of life. <h3>Methods</h3> We assessed 86 patients aged 18 to 38 years who attended outpatient clinic with acute or chronic TMJ pain and discomfort while chewing. A board of one physiatrist and a dentist (oral and maxillofacial surgeon) evaluated the patients. Previous dental surgery/ jaw injury and other dental pathologies excluded and 69 patients with myofascial pain and the history of sleep disorders like clenching or grinding teeth while sleeping were randomly divided into the oral splint (bite guard) and the kinesiotaping group. Kinesio taping was applied to the skin over TMJ in reverse “V” shape extended to inferior border of jaw muscle and to the anterolateral aspect of neck. Taping was applied two times per week for two weeks. In splint group, bite guard were used all day long for two weeks except sleeping period. Presence of locking of the the joint, clicking or crepitation sound were noted and limitation of ROM in TMJ were measured by distance between upper and lower incisives, Speech, eating and sleeping behaviors were assessed for daily living activities. Pain intensity was measured by the visual analog scale (VAS). All the parameters were evaluated before and after intervention. <h3>Results</h3> Thirty four subjects were assigned to the kinesiotaping group, and thirty five subjects were assigned to the oral splint group. Both in the kinesiotaping and splint group, the level of pain intensity was decreased and the ROM was increased significantly (p&lt;0.01), (p&lt;0.05). Comparison between the groups did not reveal significant differences in VAS and ROM. Daily eating activity and sleeping quality were improved in both groups but not in other oral activities. <h3>Conclusions</h3> Although many etiological causes of TMJ pain, for the patients with myofascial pain and fibromyalgia, kinesiotaping is as effective as oral splints like bite guards. During daily practice, the myofascial pain syndrome and fibromyalgia background should be assessed for the ideal treatment. In contrast to splinting, kinesiotaping is non-invasive, easy-to-apply intervention method and do not interrupt daily oral activities. <h3>Disclosure of Interest</h3> None declared
Retrospective analysis of cytogenetic and clinical characteristics on 65 patients with multiple myeloma
Authors: Li Yang, Jingsong He, Xiaojian Meng, Guoqing Wei, Wenjun Wu, Xiaoyan Han, Gaofeng Zheng, Weiyan Zheng, Xiujin Ye, Jimin Shi, Wanzhuo Xie, Jie Zhang, He Huang, Maofang Lin, Zhen Cai
Journal: Blood (2011)
Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes
Authors: Matthew A. Tyler, Chris B. Russell, Dirk E. Smith, James B. Rottman, Caroline J. Padro Dietz, Xuguang Hu, Martin J. Citardi, Samer Fakhri, Shervin Assassi, Amber Luong
Journal: Journal of Allergy and Clinical Immunology (2016)
Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL)
Authors: James Tracey, Mei-Jie Zhang, Kathleen A Sobocinski, Elizabeth L. Thiel, Michael J. Eckrich, Marcelo C Pasquini, Wael Saber, Daniel J. Weisdorf, Mary M. Horowitz, Mary Eapen
Journal: Blood (2010)
Immune Tolerance Induction Treatment Is Cost-Effective in Adult Patients with Long-Standing High-Responding Inhibitors
Authors: Alessandra Nunes Loureiro Prezotti, Silmara Aparecida De Lima Montalvão, Cláudia Lorenzato, Andrea Maia Oliveira, Maria do Perpétuo Socorro Vendramini Orletti, Maria Do Rosario Ferraz Roberti, Luiz Ivando Ferreira Filho, Paula Ribeiro Villaça, Erica Okazaki, Samuel de Souza Medina, Margareth Castro Ozelo
Journal: Blood (2015)
8p11.2 Translocations: Prevalence, FISH Analysis for FGFR1 and MYST3, and Clinicopathologic Correlates in a Consecutive Cohort of 13 Cases From a Single Institution.
Authors: Mrinal M Patnaik, Ryan A Knudson, Curtis A. Hanson, Rhett P Ketterling, Ayalew Tefferi
Journal: Blood (2009)
Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide
Authors: Dana E Rollison, Rami Komrokji, Ji-Hyun Lee, Shalaka S Hampras, William Fulp, Kate Fisher, Rachid Baz, Taiga Nishihori, Marta Olesnyckyj, Laurie Kenvin, Robert D. Knight, Daniel M Sullivan, Melissa Alsina, William Dalton, Kenneth H. Shain
Journal: Blood (2014)
RARE-23TWO CASES OF RARE INTRASPINAL POORLY DIFFERENTIATED NEUROENDOCRINE TUMOR WITH EXCELLENT RESPONSES TO RADIATION THERAPY
Authors: Alicia Zukas, Michael Hays, David Schiff
Journal: Neuro-Oncology (2015)

We describe two unusual cases of poorly differentiated neuroendocrine tumor of the spinal cord and leptomeninges. A 61-year-old woman developed rapidly progressive lower extremity paraparesis and sensory deficits. MRI revealed an intradural extramedullary mass levels arising from the conus extending from T12-S3, in multiple foramina, with extensive craniospinal leptomeningeal dissemination. Debulking revealed a poorly differentiated neoplasm characterized by nuclear molding and a high mitotic rate with immunohistochemical positivity for neuroendocrine markers (CD56, chromogranin, synaptophysin). Hematopoietic markers, keratin, GFAP, S100, and CD99/MIC2 were negative, and EWSR1 gene was intact by FISH. She received craniospinal irradiation of 39.6Gy in 22 fractions with a 5.4Gy boost followed by temozolomide. She remains clinically stable nineteen months since presentation, and MRI shows dramatic improvement with small remnants of enhancement at the cauda equina and thoracic thecal sac. The second case is a 65-year-old man with two months of progressive lower extremity paraparesis. He became non-ambulatory with a KPS of 40. MRI revealed an expansile intramedullary cervical cord lesion and diffuse neuroaxial leptomeningeal enhancement. Biopsy revealed a small round blue cell tumor with a markedly elevated proliferative index. Immunostaining showed diffuse positivity for CD56 and CD99/MIC2, while stains for CD45 and keratin were negative. EWSR1 and FUS genes were intact. He received craniospinal irradiation with a boost to bulky disease. His exam improved greatly and he was ambulatory four weeks after radiation with a KPS of 90. One year after radiation, he has little residual radiographic disease with an unchanged examination. For both cases, no alternative primary source was identified. Cauda equine paragangliomas have been the principal intraspinal neuroendocrine tumors described to date; we have been unable to identify other reports of primary intraspinal high grade poorly differentiated neuroendocrine tumors. Remarkably, despite extensive disease and poor performance status both our patients had excellent responses to radiation.
Intra-Tumoral Blast Heterogeneity and Implications for Minimal Residual Disease Detection in T-Cell Acute Lymphoblastic Leukemia
Authors: Nina Friesgaard Öbro, Lars Peter Ryder, Hans Ole Madsen, Mette Klarskov Andersen, Birgitte Klug Albertsen, Peder Skov Wehner, Steen Rosthoej, Nina Toft, Thomas Leth Frandsen, Kjeld Schmiegelow, Hanne Vibeke Marquart
Journal: Blood (2014)
Fracture of a self-expanding metal stent used to manage a post-vertical sleeve gastrectomy stenosis
Authors: Samuel Fernandes, Carlos Ferreira, Joao Lopes, João Raposo, José Velosa
Journal: Endoscopy (2016)

A vertical sleeve gastrectomy performed on a 33-year-old obese woman was complicated by severe stenosis of the middle of the gastric tube and a fistula at the site of the stenosis that was communicating with a perigastric abscess. Initially the patient was managed conservatively with placement of a nasoenteric tube and administration of antibiotics. This led to clinical improvement, but a Gastrografin study 2 weeks later showed persistent gastric stenosis despite closure of the fistula ([Fig. 1]). An upper gastrointestinal endoscopy (UGE) confirmed a 5-cm stenosis of the gastric tube and a covered self-expanding metal stent (SEMS; Hanarostent Esophagus Benign BS; 22/28 × 120 mm) was deployed across the stenosis ([Fig. 2]).
PTH-082 Comparison of Efficacy and Safety of Biosimilar Infliximab to Originator Infliximab in Children with Inflammatory Bowel Disease: Abstract PTH-082 Table 1
Authors: R Muhammed, T Wong, W Haller, S Protheroe, L Whyte, R Bremner
Journal: Gut (2016)

<h3>Introduction</h3> CT-P13 is the biosimilar Infliximab approved for use in Europe and it is marketed in the UK in two brand names, Remsima (NAPP pharmaceuticals) and Inflectra (Hospira pharmaceuticals). We have compared the efficacy and safety of biosimilar Infliximab to the originator Infliximab (Remicade, MSD Immunology) in our clinical practice. <h3>Methods</h3> Clinical and laboratory data of patients receiving Infliximab from January 2015 to October 2015 was collected from patient records and electronic case records. <h3>Results</h3> We have used biosimilar Infliximab (Inflectra) for all new starters of Infliximab treatment in our unit since July 2015. 24 patients (18 with Crohn’s disease (CD) and 6 with ulcerative colitis (UC)) were started on Inflectra this year. 17 patients (15 patients with Crohn’s disease and 2 with ulcerative colitis) were started on Remicade from January to July this year. A total of 72 Inflectra infusions were administered compared to 96 infusions of Remicade. Median number of infusions per patient was 3 and 6 respectively for Inflectra and Remicade. 1 patient receiving Inflectra had a major infusion reaction needing a switch of treatment to Adalimumab. This was comparable to the incidence of major infusion reaction in patients receiving Remicade (1/17). Clinical remission was achieved in 7/11 (64%) patients receiving Inflectra treatment. 8/15 (53%) children with Crohn’s disease on treatment with Remicade achieved clinical remission. 3/6 (50%) patients with UC achieved clinical remission using Inflectra. 1/2 (50%) patients with UC on Remicade achieved clinical remission. Cost of Inflectra is less than that of Remicade (100 mg vial of Inflectra costs approximately £210 and 100 mg vial of Remicade costs approximately £350). Results are summarised in Table 1. <h3>Conclusion</h3> In our clinical practice, the efficacy and safety of biosimilar Infliximab (Inflectra) is comparable to the originator Infliximab with significant cost savings offered by the use of biosimilar Infliximab. <h3>Disclosure of Interest</h3> R. Muhammed Grant/research support from: MSD immunology, Abbvie, Takeda, Speaker bureau with: Abbvie, Dr Falk, Conflict with: MSD Immunology, Takeda, Pfizer, Dr Falk, Nestle, T. Wong: None Declared, W. Haller: None Declared, S. Protheroe Grant/research support from: Tillotts Pharma, L. Whyte: None Declared, R. Bremner: None Declared
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Authors: Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Meera Tugnait, Narayana I Narasimhan, David J Dorer, David Kerstein, Victor M Rivera, Timothy Clackson, Frank G Haluska, David Ross Camidge
Journal: The Lancet Oncology (2016)
PTH-089 Childhood Environmental Factors and Trends in Inflammatory Bowel Disease
Authors: S Chetcuti Zammit, A Brincat, G Laferla, P Ellul
Journal: Gut (2016)

<h3>Introduction</h3> Genetic predisposition, does not account solely for disease aetiology. Other environmental and childhood factors might explain the rise of inflammatory bowel disease (IBD) in recent years. <h3>Methods</h3> All patients diagnosed with IBD between 2012 and 2014 at Mater Dei Hospital in Malta were included in this study. Each patient was then asked to fill in a questionnaire related to childhood factors. <h3>Results</h3> 152 patients (mean age 42.4 years sd±17.7; mean age at diagnosis 39.8 years sd±17.7) were included in this study. 55.9% were male. 65.8% patients suffered from UC. Association between Montreal classification and childhood factors: If patients were brought up with siblings, they were more likely to have an older Montreal age at diagnosis (p &lt; 0.018). The age at which patients were separated at school from their siblings was statistically related to Montreal behaviour (p &lt; 0.018). Patients who swam in a pool had a younger Montreal age at diagnosis (p &lt; 0.028). Association of type of IBD with childhood factors: When factors were assessed individually, more patients with UC than CD shared a bedroom with their siblings (p &lt; 0.003). On binary logistic regression analysis, having contracted measles (p &lt; 0.033) and mumps (p &lt; 0.021) were statistically significant in determining type of IBD our patients had. Association of childhood factors with age at diagnosis: Factors leading to an older age at diagnosis of IBD: whether patients were brought up with siblings (p &lt; 0.001), underwent cholecystectomy (p &lt; 0.002), contracted measles (p &lt; 0.001) during childhood. Factors leading to a younger age at diagnosis of IBD: whether they were vaccinated (p &lt; 0.029), if they owned fish (p &lt; 0.004), whether they went swimming (p &lt; 0.012), if they swam in a pool (p &lt; 0.001), most swimming modalities (p &lt; 0.001). Only the factors below retained statistical significance when assessed using univariate regression analysis. Sharing a bedroom with siblings(p &lt; 0.0001) and having undergone a tonsillectomy (p &lt; 0.019) predisposed to an older age at diagnosis. Sharing day nursery with siblings (p &lt; 0.002), swimming in the sea (p &lt; 0.019) and in a pool (p &lt; 0.007) all predisposed to a younger age at diagnosis of IBD. <h3>Conclusion</h3> Certain factors such as vaccination and swimming at a young age might predispose to a younger age at diagnosis of IBD. Other factors such as being brought up with siblings were protective and lead to an older age at diagnosis. Studying such factors on a bigger scale might further confirm these trends and may influence lifestyle changes. <h3>Disclosure of Interest</h3> None Declared
Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis
Authors: Farrukh Awan, Samith Thomas Kochuparambil, Michael Craig, Aaron Cumpston, Sonia Leadmon, Kathy Watkins, David Deremer, Jeremy Pantin, Vamsi Kota, Anand P. Jillella, Mehdi Hamadani
Journal: Blood (2012)